Uploaded January 2026 | Updated September 2026, 1 week ago
At the end of 2025, approximately 1 in 8 adults (about 12%) reported currently using a glucagon-like peptide-1 (GLP-1) drug.
In this episode of the podcast, Geoff Cook, CEO of Noom, and I engage in a nuanced, science-forward conversation about GLP-1 medications—and why the future of these compounds may look very different from the way they’re being used today.
In this episode, we cover:
- What Noom actually is and how they’re approaching preventive health and longevity
- What it really means to “microdose” a GLP-1 and how that differs from standard dosing
- How GLP-1s can support inflammation reduction and insulin sensitivity—beyond weight loss
- The potential impacts on brain health, cravings (including alcohol-related cravings), and behavior change
- What fertility considerations look like with GLP-1 use, including implications for polycystic ovary syndrome (PCOS)
- Which biomarkers you can track to assess whether a GLP-1 is actually working
- How peptide safety and pharmacy standards are determined, and how Noom is navigating the current regulatory landscape
This is a must-listen for anyone curious about GLP-1s but cautious about side effects, long-term safety, or the “one-size-fits-all” approach that dominates the conversation.
LIFE Network: joinlifenetwork.com
Ben Greenfield Life Website: bengreenfieldlife.com
Ben Greenfield Life Podcast: bengreenfieldlife.com/podcast
Ben Greenfield Books: shopbengreenfieldlife.com/collections/books
Instagram instagram.com/bengreenfieldfitness
Facebook facebook.com/BGFitness
X twitter.com/bengreenfield
TikTok tiktok.com/@bengreenfield
00:00 "GLP1, Peptides, & Microdosing"
05:21 Microdosing Retatrutide for Appetite
09:15 GLP1s: Regulation and Accessibility
11:25 "FDA's Compounding Quality Initiative"
14:35 "Appetite Suppression and Microdosing"
18:26 "Microdose Habits vs. Dependency"
20:51 "Building Habits Through Structure"
26:25 Inflammation, Fat Loss, Brain Health
27:47 "Food Noise and Cognitive Bandwidth"
32:22 "503A Compliance & Microdosing Protocol"
34:45 Precise Peptide Dosing Importance
39:42 Inflammation, Cholesterol, Testosterone, TASO.
42:35 "Drug Pricing and Access Issues"
46:15 Affiliate Disclosure and Transparency
47:01 "Optimizing Mind, Body, Spirit"
At the end of 2025, approximately 1 in 8 adults (about 12%) reported currently using a glucagon-like peptide-1 (GLP-1) drug.
In this episode of the podcast, Geoff Cook, CEO of Noom, and I engage in a nuanced, science-forward conversation about GLP-1 medications—and why the future of these compounds may look very different from the way they’re being used today.
In this episode, we cover:
- What Noom actually is and how they’re approaching preventive health and longevity
- What it really means to “microdose” a GLP-1 and how that differs from standard dosing
- How GLP-1s can support inflammation reduction and insulin sensitivity—beyond weight loss
- The potential impacts on brain health, cravings (including alcohol-related cravings), and behavior change
- What fertility considerations look like with GLP-1 use, including implications for polycystic ovary syndrome (PCOS)
- Which biomarkers you can track to assess whether a GLP-1 is actually working
- How peptide safety and pharmacy standards are determined, and how Noom is navigating the current regulatory landscape
This is a must-listen for anyone curious about GLP-1s but cautious about side effects, long-term safety, or the “one-size-fits-all” approach that dominates the conversation.
LIFE Network: joinlifenetwork.com
Ben Greenfield Life Website: bengreenfieldlife.com
Ben Greenfield Life Podcast: bengreenfieldlife.com/podcast
Ben Greenfield Books: shopbengreenfieldlife.com/collections/books
Instagram instagram.com/bengreenfieldfitness
Facebook facebook.com/BGFitness
X twitter.com/bengreenfield
TikTok tiktok.com/@bengreenfield
00:00 "GLP1, Peptides, & Microdosing"
05:21 Microdosing Retatrutide for Appetite
09:15 GLP1s: Regulation and Accessibility
11:25 "FDA's Compounding Quality Initiative"
14:35 "Appetite Suppression and Microdosing"
18:26 "Microdose Habits vs. Dependency"
20:51 "Building Habits Through Structure"
26:25 Inflammation, Fat Loss, Brain Health
27:47 "Food Noise and Cognitive Bandwidth"
32:22 "503A Compliance & Microdosing Protocol"
34:45 Precise Peptide Dosing Importance
39:42 Inflammation, Cholesterol, Testosterone, TASO.
42:35 "Drug Pricing and Access Issues"
46:15 Affiliate Disclosure and Transparency
47:01 "Optimizing Mind, Body, Spirit"
